Novo Nordisk told investors it expects 2026 sales and operating profit to decline—forecasting a 5–13% drop—after agreeing to U.S. price concessions for Wegovy. Executives said the company still sees strong early uptake for the Wegovy pill and cited 50,000 prescriptions within the launch window, but warned that lower cash‑pay pricing and government deals will dent near‑term revenue. The announcement triggered a sharp selloff in the company's shares as Wall Street recalibrated growth expectations in the intense GLP‑1 competitive landscape.